The global Contract Research Organization (CRO) market is set to top $93 billion in 2026, as pharma and biotech companies increasingly rely on outsourced expertise to speed up drug development and control costs. From clinical trials to regulatory affairs, CROs have become essential partners in modern R&D. Here’s what procurement teams need to know about the CRO market in 2026 — and how to build smarter partnerships.
The pharmaceutical and biotech industries are witnessing rapid growth and innovation, driving the need for efficient research and development (R&D) processes. Contract Research Organizations (CROs) have emerged as key partners providing outsourced services across various domains such as preclinical services, clinical trials management, regulatory affairs, and more.
Contract Research Organizations, are external service providers that offer specialised support to pharmaceutical and biotech companies. They play a critical role in accelerating drug development, reducing costs, and enhancing operational efficiency for their clients.
Breakdown of main services offered by CROs-
1. Preclinical Services
Preclinical testing, including in vitro and in vivo studies, to assess the safety and efficacy of drug candidates before human trials.
2. Clinical Trials Management
Planning, execution, and oversight of clinical trials, ensuring adherence to protocols, data collection, and regulatory compliance.
3. Clinical Data Management
Collection, validation, and analysis of clinical trial data, ensuring accuracy and compliance with regulatory standards.
4. Biostatistics and Statistical Analysis
Application of statistical methods to analyze clinical trial data, providing insights on efficacy, safety, and patient outcomes.
5. Regulatory Affairs
Expertise in navigating complex regulatory requirements, ensuring compliance with local and international regulations.
6. Pharmacovigilance and Drug Safety
Monitoring, evaluation, and reporting of adverse events and side effects associated with investigational drugs and marketed products.
7. Medical Writing
Preparation of regulatory documents, study protocols, investigator brochures, and other scientific and medical documents.
The FSP Model and “FSP 2.0”
Functional Service Provider (FSP) Models
Alongside traditional full-service outsourcing, many sponsors are adopting Functional Service Provider (FSP) arrangements, where a CRO supplies dedicated functional teams (e.g., biostatistics, data management, or clinical monitoring) that integrate directly into the sponsor’s own processes, rather than running the entire trial. Industry analysts describe an emerging “FSP 2.0” model for 2026, in which these partnerships rely on centralized, data-savvy teams using AI-enhanced workflows rather than pure staff augmentation, per ACL Digital’s 2026 CRO trends analysis. This hybrid approach gives sponsors more flexibility to scale specific functions up or down without committing to a single full-service vendor.
CRO vs. CDMO — What’s the Difference?
Because the two terms are often used interchangeably by non-specialists, it’s worth a short clarifying note: a Contract Research Organization (CRO) supports the research and development side of the pharma value chain — preclinical studies, clinical trial management, biostatistics, regulatory affairs, and pharmacovigilance. A Contract Development and Manufacturing Organization (CDMO) supports the manufacturing side — producing the active pharmaceutical ingredient or finished drug product at clinical or commercial scale. Some companies operate as both (a “CRDMO”), but the distinction matters for procurement teams evaluating sourcing risk, since regulatory developments like the BIOSECURE Act affect each category differently.
Contract Research Organization Market Trends
The global contract research organization (CROs) services market size is calculated at USD 77.00 billion in 2025 and is predicted to increase from USD 82.90 billion in 2026 to approximately USD 158.58 billion by 2035, growing at a CAGR of 7.49% from 2026 to 2035.
By service segment, clinical research services are expected to lead the market with roughly 41% share in 2026, and Phase I studies are projected to capture the largest phase-specific share at around 48%, reflecting continued growth in first-in-human testing volumes, per Coherent Market Insights.
Market trends and key drivers
1. Increasing Outsourcing of R&D Activities
Pharma and biotech companies are outsourcing a larger portion of their R&D activities to CROs to leverage their expertise, reduce costs, and accelerate drug development timelines.
2. Growing Focus on Specialised Therapeutic Areas
There is a rising demand for CROs with expertise in specialised therapeutic areas, such as oncology, neurology, rare diseases, and gene therapies.
3. Technological Advancements and Data-Driven Approaches
CROs are adopting advanced technologies, such as artificial intelligence (AI), machine learning (ML), and big data analytics, to enhance efficiency, data quality, and decision-making capabilities.
4. Regulatory Complexities and Compliance Requirements
The pharmaceutical industry is subject to stringent regulatory frameworks, necessitating CROs to maintain expertise in regulatory affairs and ensure compliance throughout the drug development process.
5. Global Expansion and Emerging Markets
CROs are expanding their presence in emerging markets, such as Asia-Pacific and Latin America, to tap into growing opportunities and leverage cost advantages.
AI Adoption in the CRO Industry
The Rise of AI-Enabled CRO Services
Artificial intelligence has moved from pilot projects to core infrastructure across clinical development. The AI-in-CRO-services segment is now tracked as its own market, valued at roughly $14.55 billion in 2026 and projected to grow to $18.45 billion by 2031 at an 18.45% CAGR — more than double the growth rate of the broader CRO market, according to Mordor Intelligence.
Sponsors increasingly expect CRO partners to deliver data-driven decision support throughout development, not just execution — using AI for protocol design, feasibility modeling, patient targeting, and automated data review, per Clinical Leader. The FDA issued draft guidance on AI use in clinical development in January 2025, establishing an early compliance pathway for AI-enabled trial tools, and the finalized ICH E6(R3) Good Clinical Practice guideline (adopted January 2025) reflects this shift toward technology-enabled trial oversight.
Despite the pace of adoption, most efficiency gains are currently showing up in CRO margins rather than dramatically reshaping outsourcing economics — the labor-based outsourcing model is evolving gradually rather than being disrupted overnight, per Clinical Leader’s analysis of CRO earnings trends.
Decentralized Clinical Trials (DCTs)
Decentralized and Hybrid Trial Models
Decentralized clinical trials (DCTs) — which use remote monitoring, telehealth visits, and local or home-based sample collection to reduce the burden on trial participants — have moved from experimental pilots to a standard sponsor expectation. DCT adoption is projected to grow 15–20% annually through 2026, driven by patient demand for convenience and CRO investment in remote-trial technology, per ACL Digital. Most therapeutic areas are expected to incorporate at least some degree of decentralized methodology going forward, supported by updated FDA guidance on conducting trials with decentralized elements and the European Clinical Trials Coordination Group’s 2025 recommendation paper on decentralized trial elements.
The BIOSECURE Act and CRO Sourcing Strategy
Regulatory Spotlight: The BIOSECURE Act
One of the most significant 2026 developments for pharma procurement teams is the BIOSECURE Act, signed into U.S. law in December 2025 as part of the National Defense Authorization Act. The law restricts U.S. federal agencies from procuring biotechnology equipment or services from Chinese life sciences companies designated as “biotechnology companies of concern,” with the U.S. Office of Management and Budget required to publish a formal list, per Fierce Pharma’s coverage of the legislation.
The impact is significant: an estimated 79% of biopharma companies have at least one contract with a China-based or China-owned CDMO, with $10–20 billion in annual contract value at stake, according to Vision Life Sciences’ 2026 analysis. It’s worth noting an important distinction for procurement teams: the Act primarily targets CDMO/manufacturing contracts, not CRO clinical trial operations — Western sponsors can generally still run trials in China and engage Chinese CRO partners without BIOSECURE compliance concerns, per the same analysis. Even so, the legislation is accelerating “China-plus-one” sourcing strategies and reshoring interest across the broader outsourcing landscape, which pharma procurement teams should factor into long-term CRO and CDMO partnership planning.
SWOT Analysis-
Strengths
-
Expertise in precision medicine, genomics, and biomarker-driven research
-
Strong adoption of digital tools, wearables, and remote trial technologies
-
Operational flexibility to support diverse and complex clinical programs
Weaknesses
-
Heavy dependence on sponsor pipelines and project-based revenues
-
High competition requiring continuous differentiation
-
Revenue instability without consistent new project inflow
Opportunities
-
Expansion of global clinical trials and broader patient access
-
Entry into emerging markets
-
Growing demand for CRO support in advanced therapies (gene therapy, immuno-oncology)
Threats
-
Sponsor budget cuts or pipeline shifts
-
Increasing competition from global CROs
-
Complex multi-regional regulatory requirements
-
Rapid technological evolution challenging slower adopters
How to partner better with Contract Research Organizations
In order to establish better partnerships with PAT suppliers and effectively manage costs without compromising quality, pharmaceutical procurement teams can consider the following strategies:
Clearly Define Project Requirements and Expectations
Clearly communicate project goals, timelines, deliverables, and quality expectations to ensure alignment between the pharmaceutical company and the CRO.
Foster Open Communication Channels
Establish regular communication channels, such as project meetings and status updates, to foster collaboration, address concerns, and ensure transparency.
Establish Performance Metrics and Key Performance Indicators (KPIs):
Define measurable performance metrics and KPIs to monitor the CRO’s performance, track progress, and address any deviations from agreed-upon standards.
Conduct Thorough Cost-Benefit Analyses
Evaluate the value proposition of engaging with a CRO by conducting comprehensive cost-benefit analyses, considering factors such as expertise, quality, timelines, and cost.
Explore Flexible Pricing Models and Contracts
Negotiate flexible pricing models, such as milestone-based payments or risk-sharing arrangements, to align incentives and optimize cost structures.
Streamline Processes and Eliminate Inefficiencies
Collaborate with CROs to identify and streamline inefficient processes, eliminating redundancies, and optimizing resource utilization.
Leverage Technology and Automation
Embrace technological advancements and automation solutions to improve operational efficiency, data quality, and cost-effectiveness.
Develop Long-Term Partnerships for Cost Optimization
Establish long-term partnerships with preferred CROs to leverage economies of scale, improve cost predictability, and foster continuous process improvement initiatives.
Source- Crown Bioscience
Latest Contract Research Organizations News-
Frequently Asked Questions-
1. What is a Contract Research Organization (CRO)?
A CRO is a specialised service provider that supports pharmaceutical and biotech companies with outsourced research and development activities, including clinical trials, regulatory support, data management, and laboratory services. They help sponsors accelerate development while reducing operational burden.
2. What key trends are driving the CRO market today?
Major trends include the rise of precision medicine, increased adoption of decentralised and digital clinical trial technologies, growing outsourcing by small and mid-sized biotechs, and the global expansion of clinical trials into new geographic regions.
3. What challenges do pharma companies face when working with CROs?
Common challenges include inconsistent performance across study phases, communication gaps, limited operational oversight, unexpected delays, and difficulty aligning internal expectations with CRO capabilities. Managing multiple CRO partners across regions can also add complexity.
4. How should procurement teams evaluate and select the right CRO partner?
Procurement should assess the CRO’s therapeutic expertise, past performance, global footprint, regulatory track record, technology capabilities, cost structure, and cultural fit. Reviewing case studies, KPIs, and operational processes is essential for selecting the best partner.
5. How is globalisation influencing CRO operations?
Globalisation enables CROs to run trials across diverse populations, access faster patient recruitment, and collaborate with a broader network of investigative sites. It also opens opportunities in emerging markets, though it requires strong regulatory and logistical coordination.
6. How can sponsors build stronger partnerships with CROs?
Strong partnerships are built on clear communication, well-defined roles, transparent expectations, shared risk, joint planning, and continuous performance monitoring. Long-term, strategic collaboration—rather than project-by-project engagement—often leads to better trial outcomes.
